logo
Twitter
Discord
Email
logo
Immuneering Corporation

Immuneering Corporation

NASDAQ•IMRX
CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-07-30
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Contact Information
245 Main Street, Second Floor, Cambridge, MA, 02142, United States
617-500-8080
immuneering.com
Market Cap
$194.58M
P/E (TTM)
-3.4
37
Dividend Yield
--
52W High
$10.08
52W Low
$1.10
52W Range
47%
Rank44Top 53.8%
3.7
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.38-22.45%
4-Quarter Trend

FCF

-$11.98M-11.08%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Financing Bolsters Cash Position Net cash provided by financing activities reached $226.9M, increasing total cash equivalents to $227.6M as of September 30, 2025.
Atebimetinib Clinical Data Lead candidate atebimetinib showed 86% overall survival and 53% progression free survival in updated interim data.
R&D Spending Prioritization Nine-month Research and development expenses slightly decreased 0.9% to $32.8M, prioritizing atebimetinib development.
Equity Issuance Significant Class A common stock issued increased shares outstanding to 63.5M from 31.1M since December 31, 2024.

Risk Factors

Clinical Stage Operations Company is clinical-stage oncology firm; has no approved products, making future success difficult to evaluate or predict.
Continued Operating Losses Incurred significant net losses for several years; expects recurring losses for foreseeable future, delaying profitability.
Substantial Capital Requirement Requires substantial additional capital to finance operations; inability to raise funds may force program delays or elimination.
Regulatory Approval Uncertainty FDA approval processes are lengthy, time-consuming, and inherently unpredictable regarding outcomes for product candidates.

Outlook

Pivotal Trial Dosing Planned Expects to dose first patient in pivotal Phase 3 trial for atebimetinib combination by mid-2026, pending regulatory feedback.
Focus Resources on Lead Made strategic decision to pause internal advancement of IMM-6-415, focusing resources on atebimetinib development.
Cash Runway Extended Current cash and equivalents estimated sufficient to fund operating expenses and capital requirements into 2029.
Future Regulatory Feedback Anticipates receiving regulatory feedback on pivotal Phase 3 clinical trial plans in the fourth quarter of 2025.

Peer Comparison

Revenue (TTM)

Entrada Therapeutics, Inc.TRDA
$61.52M
-71.4%
Codexis, Inc.CDXS
$52.93M
-17.9%
Assembly Biosciences, Inc.ASMB
$37.19M
+31.3%

Gross Margin (Latest Quarter)

Assembly Biosciences, Inc.ASMB
100.0%
+0.0pp
Sangamo Therapeutics, Inc.SGMO
100.0%
+4.3pp
Codexis, Inc.CDXS
71.3%
+5.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SLS$449.02M-17.8-95.2%1.2%
TRDA$436.85M-4.6-26.4%12.7%
ASMB$241.19M-5.6-59.0%1.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 19, 2026
|
EPS:-$0.31
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 12, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.38-22.4%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 13, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.40-14.9%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 5, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.42-14.3%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 20, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-2.04-8.5%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 13, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.49+14.0%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|
    Revenue: $0.00-100.0%
    |
    EPS: $-0.47+9.3%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 7, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.49-101.2%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 1, 2024|
    Revenue: $0.00-100.0%
    |
    EPS: $-1.88-0.5%
    N/A